GEN Exclusives

More »

GEN News Highlights

More »
May 9, 2012

UPenn Alumni Gift $25M for Facility Focused on BRCA-Mutated Cancers

  • The University of Pennsylvania has been gifted $25 million by alumni Mindy and Jon Gray to establish the Basser Research Center (BRC), focused on the treatment and prevention of cancers associated with hereditary BRCA mutations. Located at Penn’s Abramson Cancer Center (ACC) at the Perelman School of Medicine, the Basser Center will contribute to all stages of research related to BRCA-related cancer detection, prevention, treatment, and care.

    The gifted funds will establish a professorship, enhance core technologies including bioinformatics and DNA vaccine production, and establish the Basser Prize for cutting-edge research. The center is named after Mindy Gray’s sister, Faith Basser, who died of ovarian cancer aged 44. “We hope that the Basser Research Center will eliminate BRCA-related cancer and, in doing so, provide a road map for curing other genetic diseases,” Mindy and Jon Gray state.

    “In creating this first-of-a-kind center, the Grays’ gift endows Penn researchers and clinicians with the crucial resources reuiqred to identify innovative ways to prevent and treat inherited diseases,” adds UPenn president Amy Gutmann.

    The ACC currently supports 300 cancer research scientists, and has acted as an NIH-designated Comprehensive Cancer Center for over 30 years. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »